Displaying 96 (all) recruiting clinical trials.
-
PRESERVE Heart Study
The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS ... -
A Phase 3 Multi-Center Randomized Double-Blind Trial to Evaluate The Efficacy and Safety of Aficamten Compared To Placebo in Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
The purpose of this research study is to compare the effects of aficamten and placebo on health status and exercise capacity in participants with non-obstructive ... -
A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB WITH AND WITHOUT TIRAGOLUMAB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA
This study is testing if a new treatment works for patients with hepatocellular carcinoma (HCC) that's either very advanced or has spread to other ...
-
A Phase 3 Randomized Double-blind Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
This research study is for people who are 12 years of age or older and weigh at least 40 kg, and who have had surgery ...
-
A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician s Choice in Patients with Triple Negative Breast Cancer That Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
This is a large global study for people with a type of breast cancer called triple-negative breast cancer (TNBC). It's happening in many hospitals ...
-
A Phase 3 Randomized Double-Blind Placebo- and Active-Comparator- Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma
This study wants to find out if a new treatment called V940, when used with pembrolizumab, has fewer side effects and is more effective than ...